IDEAYA Biosciences Collaborates with Biocytogen to Develop Bispecific ADC Program for Cancer Treatment
Shots:
- IDEAYA Biosciences & Biocytogen have signed an option and license agreement, under which IDEAYA gets an option to secure exclusive global rights of FIC B7H3/PTK7 topoisomerase-I-payload bispecific ADC program
- Biocytogen is entitled to receive an upfront, option exercise fee (if IDEAYA exercises its option) & $100M milestones, making it a total deal value of $406.5M, plus net-sales-based single-digit royalties
- The non-clinical study of bispecific ADC has demonstrated its ability to be used alone & in addition to various IDEAYA's DDR-based therapies such as IDE161 (PARG inhibitor). A development candidate nomination is anticipated during H2’24
Ref: IDEAYA Biosciences | Image: IDEAYA Biosciences & Biocytogen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
